Author

Stefan Schreiber

EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD STUDY AND LIBERTY-UC STUDY
EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD STUDY AND LIBERTY-UC STUDY

Stefan Schreiber  et al.

SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES
SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES

Stefan Schreiber  et al.

TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION
TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION

EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY
EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY

SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY
SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY

Precision medicine with precision tools in Crohn’s disease: can we translate science into clinical practice? (Takeda)
Precision medicine with precision tools in Crohn’s disease: can we translate science into clinical practice? (Takeda)

Stefan Schreiber  et al.

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS
DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

Stefan Schreiber  et al.

MICROBIOME MODIFICATION AND IMPROVEMENT OF SIGNS AND SYMPTOMS OF COVID-19: ILEOCOLONIC-RELEASE NICOTINAMIDE IN A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
MICROBIOME MODIFICATION AND IMPROVEMENT OF SIGNS AND SYMPTOMS OF COVID-19: ILEOCOLONIC-RELEASE NICOTINAMIDE IN A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

Stefan Schreiber  et al.

CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL
CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL

Stefan Schreiber  et al.

EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE
EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE

Stefan Schreiber  et al.

RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES
RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES

Stefan Schreiber  et al.

CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS
CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS

Stefan Schreiber  et al.

BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY
BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY

Stefan Schreiber  et al.

ANALYSIS OF BASELINE CHARACTERISTICS ASSOCIATED WITH CLINICAL RESPONSE TO USTEKINUMAB IV RE-INDUCTION STRATEGY IN PATIENTS WITH CROHN’S DISEASE IN THE POWER TRIAL
ANALYSIS OF BASELINE CHARACTERISTICS ASSOCIATED WITH CLINICAL RESPONSE TO USTEKINUMAB IV RE-INDUCTION STRATEGY IN PATIENTS WITH CROHN’S DISEASE IN THE POWER TRIAL

Stefan Schreiber  et al.

Refining the Journey in the Treatment of IBD with Subcutaneous Infliximab (Celltrion Healthcare) (Complete Session)
Refining the Journey in the Treatment of IBD with Subcutaneous Infliximab (Celltrion Healthcare) (Complete Session)

Stefan Schreiber  et al.

COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL
COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL

Stefan Schreiber  et al.

HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE AMONG PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR AND CONCOMITANT THERAPIES: RESULTS FROM THE ETRASIMOD ELEVATE UC CLINICAL PROGRAMME
HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE AMONG PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR AND CONCOMITANT THERAPIES: RESULTS FROM THE ETRASIMOD ELEVATE UC CLINICAL PROGRAMME

Stefan Schreiber  et al.

BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE

Stefan Schreiber  et al.

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY

Stefan Schreiber  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Stefan Schreiber  et al.

Item 21 - 40 / 86
1
2
3 4 5